ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ADMA BIOLOGICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.07+0.39 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $2.55B
- P/E (TTM)
- 15.8
- Dividend yield
- –
ADMA BIOLOGICS, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing [Member] | $493.00M | $415.81M | $249.74M | $144.07M | $74.94M | $36.67M | – | – | – | – | 96.6% | +18.6% |
| Plasma Collection Centers [Member] | $17.03M | $10.51M | $8.33M | $9.87M | $5.86M | $5.40M | – | – | – | – | 3.3% | +62.1% |
| Plasma Collection Centers | – | – | – | – | – | $5.40M | $7.03M | $10.04M | $11.64M | $10.52M | – | – |
| Research And Development Member | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Corporate [Member] | – | – | $143.00K | $143.00K | $143.00K | $142.83K | $142.83K | $142.83K | $142.83K | $142.83K | – | – |
| ADMA BioManufacturing | – | – | – | – | – | $36.67M | $22.18M | $6.80M | $10.98M | $0 | – | – |
| Consolidated (member) | – | – | – | – | – | $42.22M | $29.35M | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing [Member] | – | – | $47.53M | $879.00K | -$29.29M | -$46.90M | – | – | – | – | – |
| Plasma Collection Centers [Member] | – | – | -$4.05M | -$17.91M | -$12.06M | -$4.41M | – | – | – | – | – |
| Plasma Collection Centers | – | – | – | – | – | -$4.41M | -$1.34M | -$4.47M | -$2.17M | -$1.29M | – |
| Research And Development Member | – | – | – | – | – | – | – | – | – | -$7.69M | – |
| Corporate [Member] | – | – | -$21.85M | -$22.34M | -$17.02M | -$13.60M | -$10.73M | -$10.19M | -$17.34M | -$16.04M | – |
| ADMA BioManufacturing | – | – | – | – | – | -$46.90M | -$29.36M | -$45.63M | -$19.80M | $0 | – |
| Consolidated (member) | – | – | – | – | – | -$64.91M | -$41.42M | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Revenue [Member] | – | – | – | $142.83K | $142.83K | $142.83K | – | – | – | – | – | – |
| Product Revenue [Member] | – | – | – | $153.94M | $80.80M | $42.08M | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $504.07M | $410.15M | $244.88M | $146.43M | $70.63M | $36.55M | – | – | – | – | 98.8% | +22.9% |
| International [Member] | $6.11M | $16.31M | $13.33M | $7.65M | $10.32M | $5.67M | – | – | – | – | 1.2% | -62.6% |
From the segment and revenue-disaggregation notes of Adma Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.